We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.29 | -1.00% | 28.63 | 28.91 | 28.51 | 28.895 | 11,187,770 | 17:38:10 |
By Chris Wack
Nektar Therapeutics shares were up 5% to $17.10 after the company said it entered into a new oncology clinical collaboration with Merck KGaA and Pfizer Inc.
The deal is for the company to evaluate the maintenance regimen of NKTR-255, Nektar's interleukin-15 receptor agonist, in combination with avelumab, a PD-L1 inhibitor, in patients with locally advanced or metastatic urothelial carcinoma in a Phase II study.
NKTR-255 is wholly owned by Nektar and is currently being evaluated in two separate clinical studies in both liquid and solid tumors. The novel IL-15 agonist is designed to activate the IL-15 pathway to expand both natural killer cells and memory CD8+ T cell populations.
Avelumab, which is marketed in the U.S. as Bavencio, is co-developed and co-commercialized by Merck KGaA and Pfizer Inc.
Under the new collaboration, Merck KGaA and Pfizer Inc. will include the combination of NKTR-255 plus avelumab in the study. Nektar will supply NKTR-255 for the trial. Nektar and the Merck KGaA-Pfizer alliance will each maintain existing global commercial rights to their respective medicines. The study is expected to begin enrolling patients in the first quarter of 2022.
Nektar stock hit its 52-week low of $12.92 on Aug. 20.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 21, 2021 13:29 ET (17:29 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions